Cerus Q4 Revenue Reaches $64.6M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy CERS?
Reports Q4 revenueu $64.6M, consensus $59.31M. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' president and chief executive officer. "This translated into record product revenue of over $206 million, a narrowing of our GAAP net loss, and positive non-GAAP adjusted EBITDA for the second consecutive year. Looking ahead to 2026, we remain focused on improving global access to our INTERCEPT technologies, advancing our product development programs and building upon the solid financial foundation we have established."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CERS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CERS
Wall Street analysts forecast CERS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.820
Low
4.00
Averages
4.50
High
5.00
Current: 1.820
Low
4.00
Averages
4.50
High
5.00
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cerus Corporation Appoints New CEO Vivek Jayaraman
- Executive Appointment: Cerus Corporation has appointed Vivek Jayaraman as CEO effective July 1, 2026, who has been with the company since 2016 and has served as COO since 2020, showcasing strong leadership capabilities.
- Revenue Growth: Under Jayaraman's leadership, Cerus has grown its annual product revenue from less than $40 million to over $200 million by 2025, indicating robust market performance and sustained growth potential.
- Future Outlook: Cerus expects a 14% increase in revenue for 2025 and has provided guidance for 2026, reflecting the company's confidence in its strategic planning and future development.
- Market Reaction: Following the announcement, Cerus's stock price experienced a slight after-hours decline of 0.0% to $1.805, indicating a cautious market sentiment regarding the new CEO's appointment.
See More
Cerus (CERS) Q4 2025 Earnings Call Transcript
See More
Cerus Reports Q4 2025 Financial Results with Revenue Growth
- Revenue Growth: Cerus reported Q4 2025 revenue of $64.6 million, reflecting a solid performance compared to the previous year, which is expected to drive future business expansion.
- Rising Operating Expenses: Total operating expenses for Q4 2025 were $37.2 million, up 7% from $34.8 million in the prior year, indicating ongoing investments in R&D and workforce that may impact short-term profitability.
- Increased R&D Spending: R&D expenses for Q4 were $16.4 million, up from $15.4 million year-over-year, with total annual R&D costs reaching $67.7 million, primarily due to higher government contract costs and development expenses, highlighting the company's commitment to innovation.
- Higher SG&A Costs: Selling, general, and administrative expenses for Q4 2025 totaled $20.8 million, compared to $19.3 million in the prior year, with annual SG&A expenses at $80.9 million, reflecting ongoing spending in marketing and management that could affect overall profit margins.
See More
Cerus Scheduled to Announce Q4 Earnings on March 2nd
- Earnings Announcement: Cerus is set to release its Q4 earnings on March 2nd after market close, with a consensus EPS estimate of -$0.01, indicating stability in profitability year-over-year.
- Revenue Expectations: Analysts project Cerus will report revenues of $59.31 million for Q4, reflecting a 4.5% year-over-year increase, which highlights the company's growth potential and sustained product demand in the market.
- Future Outlook: Cerus anticipates a 14% increase in topline revenue by 2025, showcasing confidence in future market opportunities and potentially attracting more investor interest in its long-term growth trajectory.
- Quant Rating Insights: Seeking Alpha's Quant Rating on Cerus provides a detailed analysis of historical financial data, aiding investors in understanding the company's financial health and competitive position within the industry.
See More
Cerus Corporation to Present at TD Cowen Health Care Conference
- Conference Presentation: Cerus Corporation's management is scheduled to present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. EST, highlighting advancements in blood safety.
- Live Webcast: The event will be accessible via a live webcast on Cerus's Investor Relations page, allowing global investors to stay informed about the company's strategic direction and business developments, with a replay available for 90 days post-event.
- Product Overview: Cerus is dedicated to developing and supplying pathogen-protected blood components, with its INTERCEPT Blood System globally recognized for ensuring blood safety, meeting the needs of hospitals and patients alike.
- Regulatory Progress: The INTERCEPT red blood cell system is currently under regulatory review in Europe and in late-stage clinical development in the U.S., indicating the company's potential for global market expansion and ongoing commitment to innovation.
See More
Cerus Corporation to Present at TD Cowen Health Care Conference
- Conference Schedule: Cerus Corporation's management is set to present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. EST, highlighting its leadership in the global blood products sector.
- Live Webcast: The event will be accessible via a live webcast on Cerus's Investor Relations page, allowing global investors to stay updated on the company's latest developments, with a 90-day replay available to ensure widespread information dissemination.
- Product Overview: Cerus is dedicated to safeguarding the world's blood supply, with its INTERCEPT Blood System being the only pathogen reduction system globally to receive both CE mark and FDA approval, showcasing its technological edge in blood safety.
- R&D Progress: The INTERCEPT red blood cell system is currently under regulatory review in Europe and in late-stage clinical development in the U.S., indicating the company's ongoing commitment to innovation in blood products and its market potential.
See More
Cerus Corporation Appoints New CEO Vivek Jayaraman
- Executive Appointment: Cerus Corporation has appointed Vivek Jayaraman as CEO effective July 1, 2026, who has been with the company since 2016 and has served as COO since 2020, showcasing strong leadership capabilities.
- Revenue Growth: Under Jayaraman's leadership, Cerus has grown its annual product revenue from less than $40 million to over $200 million by 2025, indicating robust market performance and sustained growth potential.
- Future Outlook: Cerus expects a 14% increase in revenue for 2025 and has provided guidance for 2026, reflecting the company's confidence in its strategic planning and future development.
- Market Reaction: Following the announcement, Cerus's stock price experienced a slight after-hours decline of 0.0% to $1.805, indicating a cautious market sentiment regarding the new CEO's appointment.
See More
Cerus (CERS) Q4 2025 Earnings Call Transcript
See More
Cerus Reports Q4 2025 Financial Results with Revenue Growth
- Revenue Growth: Cerus reported Q4 2025 revenue of $64.6 million, reflecting a solid performance compared to the previous year, which is expected to drive future business expansion.
- Rising Operating Expenses: Total operating expenses for Q4 2025 were $37.2 million, up 7% from $34.8 million in the prior year, indicating ongoing investments in R&D and workforce that may impact short-term profitability.
- Increased R&D Spending: R&D expenses for Q4 were $16.4 million, up from $15.4 million year-over-year, with total annual R&D costs reaching $67.7 million, primarily due to higher government contract costs and development expenses, highlighting the company's commitment to innovation.
- Higher SG&A Costs: Selling, general, and administrative expenses for Q4 2025 totaled $20.8 million, compared to $19.3 million in the prior year, with annual SG&A expenses at $80.9 million, reflecting ongoing spending in marketing and management that could affect overall profit margins.
See More
Cerus Scheduled to Announce Q4 Earnings on March 2nd
- Earnings Announcement: Cerus is set to release its Q4 earnings on March 2nd after market close, with a consensus EPS estimate of -$0.01, indicating stability in profitability year-over-year.
- Revenue Expectations: Analysts project Cerus will report revenues of $59.31 million for Q4, reflecting a 4.5% year-over-year increase, which highlights the company's growth potential and sustained product demand in the market.
- Future Outlook: Cerus anticipates a 14% increase in topline revenue by 2025, showcasing confidence in future market opportunities and potentially attracting more investor interest in its long-term growth trajectory.
- Quant Rating Insights: Seeking Alpha's Quant Rating on Cerus provides a detailed analysis of historical financial data, aiding investors in understanding the company's financial health and competitive position within the industry.
See More
Cerus Corporation to Present at TD Cowen Health Care Conference
- Conference Presentation: Cerus Corporation's management is scheduled to present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. EST, highlighting advancements in blood safety.
- Live Webcast: The event will be accessible via a live webcast on Cerus's Investor Relations page, allowing global investors to stay informed about the company's strategic direction and business developments, with a replay available for 90 days post-event.
- Product Overview: Cerus is dedicated to developing and supplying pathogen-protected blood components, with its INTERCEPT Blood System globally recognized for ensuring blood safety, meeting the needs of hospitals and patients alike.
- Regulatory Progress: The INTERCEPT red blood cell system is currently under regulatory review in Europe and in late-stage clinical development in the U.S., indicating the company's potential for global market expansion and ongoing commitment to innovation.
See More
Cerus Corporation to Present at TD Cowen Health Care Conference
- Conference Schedule: Cerus Corporation's management is set to present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. EST, highlighting its leadership in the global blood products sector.
- Live Webcast: The event will be accessible via a live webcast on Cerus's Investor Relations page, allowing global investors to stay updated on the company's latest developments, with a 90-day replay available to ensure widespread information dissemination.
- Product Overview: Cerus is dedicated to safeguarding the world's blood supply, with its INTERCEPT Blood System being the only pathogen reduction system globally to receive both CE mark and FDA approval, showcasing its technological edge in blood safety.
- R&D Progress: The INTERCEPT red blood cell system is currently under regulatory review in Europe and in late-stage clinical development in the U.S., indicating the company's ongoing commitment to innovation in blood products and its market potential.
See More
